文献速递中医内科中药与中成药合理使用

中草药治疗重症肌无力的系统评价与Meta分析

Chinese herbal medicine for myasthenia gravis: A systematic review and meta-analysis of randomized clinical trials.
PubMed 文献 · Integr Med Res · 2021-11-10

Meta分析显示,黄芪复方联合常规治疗可降低症状评分(MD=-3.56,95%CI -4.86至-2.26),且中草药组不良事件更少(RR=0.13,95%CI 0.06至0.30)。证据质量中至低,提示中草药作为附加治疗可能改善症状且更安全。

要点

  • 黄芪复方联合常规治疗可能额外改善重症肌无力症状。
  • 中草药组不良事件发生率低于常规治疗组。
  • 证据质量中至低,需更多高质量试验验证。

核心结论

  • 9种中草药可能改善重症肌无力症状,黄芪复方联合常规治疗可能带来额外获益。
  • 中草药作为附加治疗可能比单用常规治疗更安全。

研究设计与样本

  • 系统评价与Meta分析,检索7个数据库及临床试验注册库至2021年7月。
  • 采用ROB 2工具评估研究质量,GRADE评估整体证据质量。

主要发现

  • 除常规治疗外,9种中草药可降低重症肌无力症状评分。
  • 黄芪复方联合常规治疗(溴吡斯的明或泼尼松或两者)较常规治疗降低症状评分(MD=-3.56,95%CI -4.86至-2.26)。
  • 中草药组不良事件较少:中草药组3/247,对照组52/245(RR=0.13,95%CI 0.06至0.30,9项RCT,共492例参与者)。
  • 对生活质量的影响结果不一致。

关键数值与推荐

  • 黄芪复方联合常规治疗降低症状评分:MD=-3.56(95%CI -4.86至-2.26)。
  • 不良事件风险比:RR=0.13(95%CI 0.06至0.30),基于9项RCT共492例参与者。

临床怎么用

  • 可考虑在常规治疗基础上加用中草药(如黄芪复方)以改善重症肌无力症状。
  • 中草药附加治疗可能减少不良事件,但需结合证据质量中至低谨慎决策。

局限性

  • 现有证据质量中至低,结果需谨慎解读。
  • 仅6项RCT(研究黄芪复方)纳入Meta分析,部分结果异质性可能影响结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myasthenia Gravis (MG) is a disorder of neuromuscular transmission bringing mild ocular weakness to severe generalized muscle weakness and disability. The conventional treatments have long-term side effects, and Chinese herbal medicines (CHM) have shown possible effect and safety for MG patients, but the existing evidence was not robust enough and the results were out of date. METHODS: Searching for randomized controlled trials (RCTs) was conducted in 7 databases and clinical trial registries until July 2021. The ROB 2 tool was used to assess the study quality and GRADE was used to assess the quality of whole evidence. Meta-analyses were conducted and the results were presented as risk ratio (RR) or mean difference (MD) with 95% confidence interval (CI). RESULTS: Nineteen RCTs (1283 participants) testing 13 kinds of CHM with adequate randomization were included and six RCTs investigating Compound Huangqi were included in the meta-analyses. In addition to conventional treatment, nine CHMs reduced symptom scores of MG. Compound Huangqi plus conventional treatment (pyridostigmine bromide or prednisone or both) reduced the symptom scores compared with conventional treatment (MD = -3.56, 95%CI -4.86 to -2.26). Less adverse events happened in the CHM groups (3/247 in the CHM groups, 52/245 in the control groups, RR = 0.13, 95%CI 0.06 to 0.30, 9 RCTs, a total of 492 participants). The effect on quality of life was inconsistent. CONCLUSION: Nine CHMs could probably bring benefit for MG symptom improvement. Moderate to low certainty of evidence supported Compound Huangqi added-on conventional treatment probably bring extra benefit of improving MG symptoms. Adding CHMs could be safer than giving only conventional treatment. STUDY REGISTRATION: The protocol was registered in PROSPERO (ID: 32718).

来源:Integr Med Res,查看原文。版权归原作者所有。

引用

  1. Zhu SJ, Wang RT, Yu ZY, et al. Chinese herbal medicine for myasthenia gravis: A systematic review and meta-analysis of randomized clinical trials. Integr Med Res. 2021. PMID: 35024335. doi:10.1016/j.imr.2021.100806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。